News >

Expert Highlights Atezolizumab/Bevacizumab Combo in RCC

Brandon Scalea
Published: Friday, Jul 06, 2018

Brian Rini, MD

Brian Rini, MD

The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) could prove to be a practice-changing regimen in the kidney cancer armamentarium, said Brian I. Rini, MD. 

Data from the IMmotion 151 trial showed that the combination compared with sunitinib (Sutent) decreased disease progression or death by 26% for patients with previously untreated PD-L1–positive metastatic renal cell carcinoma.1

Median progression-free survival (PFS) for those with PD-L1 expression on >1% of immune cells (n = 362) was a coprimary endpoint of the study along with overall survival (OS). Results showed that there was a 3.5-month improvement in median PFS at 11.2 months with atezolizumab/bevacizumab and 7.7 months with sunitinib (HR, 0.74; 95% CI, 0.57-0.96; P = .0217).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication